Cheonan, South Korea, 14 September 2023 – MGI, a company committed to building core tools and technology to lead life science, today announced an MOU with Bio-Medical Science Co., Ltd. (“BMS”) to expand genomics solutions in South Korea by leveraging MGI’s cutting-edge technology. The MOU is expected to facilitate collaborations to localize MGI’s manufacturing capabilities for selected genetic sequencers and reagents in South Korea via BMS, providing the market with state-of-the-art products adapted to local needs, helping advance genomic research and clinical diagnostics.
MGI and Bio-Medical Science Sign MOU to Deliver Cutting-Edge Sequencing Platforms and Reagents to South Korea
“This MOU marks a key milestone for the development of genomics in South Korea as we introduce localized, high-quality and cost-effective solutions powered by our proprietary DNBSEQ™ technology,” said Roy Tan, General Manager of MGI Asia Pacific. “By joining forces with our partner BMS, MGI aims to facilitate more widespread adoption of genomics, multi-omics, metagenomics and related applications locally in South Korea.”
Under the MOU, BMS and MGI will collaborate on licensing, supply, manufacturing, and distribution of selected genetic sequencers and reagents in South Korea. Leveraging BMS’ strong local network for sales and distribution alongside MGI’s innovative technology, South Korea is set to further unlock the potential of large-scale genomics, clinical studies, and microbiome research.
“Amidst the rapidly growing high-throughput sequencing market in South Korea, we have noticed a mismatch between demand and supply and hope to eliminate access barriers by bringing products and solutions that are efficient, convenient and suited to local needs,” said Kangsan D. Kim, Director of Marketing & Communications at BMS. “We are excited to partner with MGI to accelerate the localization of their cutting-edge genomics products, including sequencers such as DNBSEQ-G99.”
The relationship between MGI and BMS dates back to 2019, when BMS became the first company in the Asia Pacific region to join MGI’s Global Sequencer User Program (SUP), promoting the development of genetic technologies and applications through customized products and services. Earlier this year, the companies also partnered to establish a joint Customer Experience Center (CEC) in South Korea, giving local customers first-hand access to MGI’s newest technologies and products.
About BMS
Bio-Medical Science Co. Ltd. (“BMS”) is a leading company in the Korean life science distribution sector. Established in 1988, its headquarters is based in Gangnam, Seoul, with a network of branches and a dedicated logistics distribution centre spanning the nation. Its clients include major academic and governmental institutions, as well as renowned research and diagnostics centres.
Products are for Research Use Only and not for use in diagnostic procedures unless specifically noted.
